Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xin'an Jianpi Tongbi is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of rheumatoid arthritis (RA). It is a combination therapy consisting of two specific TCM products: Xinfeng Capsule (XFC) and Huangqinqingrechubi Capsule (HQC). The formulation is designed to address multiple TCM syndromes associated with RA, including cold-dampness, dampness-heat, blood stasis, and dampness stagnancy due to spleen deficiency. Clinical research indicates that the formulation significantly improves patient-reported outcomes, such as the Self-Perception of Patient (SPP) scale, and reduces systemic inflammatory markers, including the platelet-to-lymphocyte ratio (PLR), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). It is primarily studied and utilized within the clinical setting of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xin'an Jianpi Tongbi.